#United States #New York #Securities Class Action #Faruqi & Faruqi #uniQure

Legal Notice: uniQure Class Action

Faruqi & Faruqi, LLP is spearheading an investigation into potential claims against uniQure N.V., a company publicly listed on NASDAQ under the symbol QURE. The firm is reminding investors about the approaching deadline of April 13, 2026, to participate as a lead plaintiff in a federal securities class action lawsuit initiated against uniQure. This is an essential opportunity for those who have suffered financial losses due to the company's actions between September 24, 2025, and October 31, 2025.

Key Issues Addressed in the Lawsuit
The class action lawsuit revolves around allegations that uniQure and its executives may have engaged in unlawful practices by disseminating misleading information to investors. It is widely reported that they failed to disclose crucial information regarding the company’s pivotal study, particularly around FDA approvals and the purported success of their treatments. Below are the primary concerns highlighted in the complaint:

• - The design of uniQure's pivotal study was not fully authorized by the FDA as previously claimed.
• - Executives allegedly minimized the implications of the study's results, which could lead to delays in submitting their Biologics License Application (BLA).
• - Statements made by the company about its business trajectory lacked credibility, leading to significant financial ramifications for investors.

Impact of Recent Developments
On November 3, 2025, uniQure publicly acknowledged that the FDA had revised its position, indicating that data from its earlier studies did not satisfactorily support an application for expedited approval. This revelation contradicted earlier assurances that led many investors to believe a rapid approval process was imminent. In response to this news, shares of uniQure plunged dramatically, marking a 49% decrease from $67.69 to $34.29 in a single day. Such a collapse has prompted urgent discussions regarding investor rights and the possibility of compensation through legal avenues.

Call to Action
Faruqi & Faruqi urges any investors who experienced losses during this time to consider stepping up as lead plaintiffs or to participate in this collective legal action. Acting to uphold investor rights is essential in cases like this, where large corporations may neglect their fiduciary duties. Participation allows investors not only to seek financial recovery but also hold the company accountable for potential misconduct.

How to Get Involved
Investors interested in learning more about the uniQure class action suit, or those who wish to step forward as potential plaintiffs, can reach out directly to James (Josh) Wilson, a partner at Faruqi & Faruqi, via phone at 877-247-4292 or through his direct line at 212-983-9330 (Extension: 1310). Additionally, further insights and updates can be accessed online at Faruqi Law.

Confidentiality Assurance
All communications with Faruqi & Faruqi are handled with utmost confidentiality, providing a safe environment for sharing sensitive information, including whistleblower insights, past employee information, and any other relevant data regarding uniQure's conduct.

This notice emphasizes the critical nature of the situation and encourages affected investors to act swiftly ahead of the outlined deadline.